Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 07 2025
0mins
Source: Globenewswire
Halneuron Phase 2b Study Update: Dogwood Therapeutics is on track to present interim data from its Phase 2b study of Halneuron, a treatment for chemotherapy-induced neuropathic pain, in Q4 2025, with low discontinuation rates indicating good tolerance among participants.
Company Overview and Future Plans: Dogwood Therapeutics focuses on developing non-opioid treatments for pain and fatigue-related disorders, with ongoing research into Halneuron's efficacy and plans for further clinical trials, including an antiviral program targeting conditions related to herpesvirus reactivation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
